Share This Page
Drug Price Trends for VYLIBRA
✉ Email this page to a colleague

Average Pharmacy Cost for VYLIBRA
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
VYLIBRA 28 TABLET | 50102-0235-11 | 0.11180 | EACH | 2025-01-22 |
VYLIBRA 28 TABLET | 50102-0235-13 | 0.11180 | EACH | 2025-01-22 |
VYLIBRA 28 TABLET | 50102-0235-11 | 0.11128 | EACH | 2024-12-18 |
VYLIBRA 28 TABLET | 50102-0235-13 | 0.11128 | EACH | 2024-12-18 |
VYLIBRA 28 TABLET | 50102-0235-11 | 0.10106 | EACH | 2024-11-20 |
VYLIBRA 28 TABLET | 50102-0235-13 | 0.10106 | EACH | 2024-11-20 |
VYLIBRA 28 TABLET | 50102-0235-11 | 0.12935 | EACH | 2024-10-23 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for VyLibra
Introduction to VyLibra
VyLibra is an AB-rated generic oral contraceptive, containing the active ingredients norgestimate and ethinyl estradiol. It is designed to prevent pregnancy and is available in a monophasic administration regimen, although other generic versions like Tri-VyLibra Lo follow a triphasic regimen[4].
Market Demand and Competition
Market Demand
The demand for oral contraceptives, including VyLibra, remains steady due to their effectiveness and widespread use. The need for affordable and reliable contraceptive options drives the demand for generic alternatives like VyLibra. This demand is further bolstered by the established market for brand-name counterparts such as Ortho-Cyclen-28, Estarylla, and others[1][4].
Competition
The market for oral contraceptives is highly competitive, with numerous brand-name and generic options available. VyLibra competes directly with other generic and brand-name oral contraceptives. However, its AB-rated status, indicating bioequivalence to brand-name versions, helps it maintain a strong market position. The presence of multiple generic versions, such as Tri-VyLibra Lo, also influences the competitive landscape[1][4].
Pricing and Cost Analysis
Current Pricing
The pricing of VyLibra varies depending on the distributor and the location. On average, a 28-tablet pack of VyLibra can cost around $18 to $40 without insurance, making it a more affordable option compared to some brand-name counterparts. For example, the cost for a supply of 28 tablets can be as low as $18 at some pharmacies[5].
Cost Comparison
Generic vs. Brand Name: VyLibra, as a generic, is generally cheaper than brand-name oral contraceptives. For instance, Ortho Tri-Cyclen Lo, a brand-name equivalent, can cost significantly more, often in the range of $70 to $100 for a 28-tablet pack[1].
Insurance Coverage: Many insurance plans cover VyLibra, which can reduce the out-of-pocket cost for consumers. Under some Medicare Part D plans, the cost can be as low as $10 to $25 per month, depending on the tier and coverage[1].
Price Projections
Short-Term Projections
In the short term, the price of VyLibra is likely to remain stable due to its established market presence and the competitive nature of the generic pharmaceutical market. Any significant price changes would likely be driven by changes in raw material costs, manufacturing expenses, or shifts in market demand. The overall drug price inflation rate projected at 3.81% for 2025 may have a minimal impact on VyLibra's pricing due to its generic status and competitive market[2].
Long-Term Projections
Market Saturation: As more generic versions of oral contraceptives enter the market, there could be downward pressure on prices. However, VyLibra's reputation and bioequivalence to brand-name products should help it maintain its market share.
Regulatory Changes: Changes in healthcare policies or regulations could impact the pricing and availability of VyLibra. For instance, expanded insurance coverage or government initiatives to reduce healthcare costs could lead to lower prices for consumers.
Technological Advancements: Advances in pharmaceutical technology might lead to more efficient manufacturing processes, potentially reducing the cost of production and, subsequently, the retail price. The growing adoption of artificial intelligence in drug discovery could also influence long-term pricing strategies[3].
Distribution and Accessibility
Distribution Channels
VyLibra is distributed through various channels, including major pharmaceutical distributors such as AmerisourceBergen, ANDA, ASD Healthcare, Cardinal Health, McKesson, and Morris & Dickson. This widespread distribution ensures that the product is readily available to healthcare providers and pharmacies across the country[4].
Accessibility
The drug is available in a 28-tablet blister pack, which includes 21 active tablets and 7 placebo tablets. This packaging helps in ease of administration and adherence to the treatment regimen. The availability of VyLibra through multiple distributors and its inclusion in many insurance plans enhance its accessibility to a broad range of consumers[4].
Regulatory and Safety Considerations
Safety Profile
The use of VyLibra, like other combination oral contraceptives (COCs), is associated with certain risks. These include the increased risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors. Common adverse reactions include headache/migraine, abdominal/gastrointestinal pain, vaginal infection, and mood disorders[4].
Regulatory Environment
Changes in healthcare policies and regulatory environments can significantly impact the pricing and availability of VyLibra. For example, expanded insurance coverage or new government initiatives aimed at reducing healthcare costs could affect the market dynamics of oral contraceptives.
Market Trends and Future Outlook
Growing Demand for Generics
The increasing demand for generic medications due to their affordability and bioequivalence to brand-name drugs is a significant trend. This trend is expected to continue, driven by consumer preference for cost-effective healthcare options.
Technological Advancements
The integration of artificial intelligence and other advanced technologies in drug discovery and manufacturing is expected to be a prime trend in the coming years. These advancements could lead to more efficient production processes, potentially reducing costs and enhancing the competitiveness of generic drugs like VyLibra[3].
Expanding Indications
While VyLibra is primarily used for contraception, the expanding indications for other medications, such as GLP-1 agents for cardiovascular risk reduction, highlight the potential for broader therapeutic applications of oral contraceptives in the future. However, this would require significant clinical evidence and regulatory approvals[2].
Key Takeaways
- Stable Demand: The demand for oral contraceptives like VyLibra remains steady due to their effectiveness and widespread use.
- Competitive Pricing: VyLibra is generally cheaper than brand-name oral contraceptives, with prices ranging from $18 to $40 for a 28-tablet pack.
- Insurance Coverage: Many insurance plans cover VyLibra, reducing out-of-pocket costs for consumers.
- Distribution: VyLibra is widely distributed through major pharmaceutical distributors, ensuring broad accessibility.
- Regulatory and Safety Considerations: The drug carries risks such as increased thrombosis and common adverse reactions, and is subject to regulatory changes that could impact pricing and availability.
- Future Outlook: Technological advancements and growing demand for generics are expected to influence the market dynamics of VyLibra in the long term.
FAQs
What is VyLibra used for?
VyLibra is used as an oral contraceptive to prevent pregnancy. It contains the active ingredients norgestimate and ethinyl estradiol.
How much does VyLibra cost?
The cost of VyLibra can range from $18 to $40 for a 28-tablet pack, depending on the pharmacy and insurance coverage.
Is VyLibra covered by insurance?
Yes, many insurance plans cover VyLibra, which can significantly reduce the out-of-pocket cost for consumers.
What are the common side effects of VyLibra?
Common side effects include headache/migraine, abdominal/gastrointestinal pain, vaginal infection, and mood disorders.
How is VyLibra distributed?
VyLibra is distributed through major pharmaceutical distributors such as AmerisourceBergen, ANDA, ASD Healthcare, Cardinal Health, McKesson, and Morris & Dickson.
Sources
- Drug Patent Watch: Market Analysis and Financial Projection for Tri-VyLibra Lo Tablets.
- Vizient Inc.: Vizient projects drug price inflation at 3.81%.
- The Insight Partners: Small Molecule Drug Discovery Market Size, Share by 2031.
- Afaxys Pharma: VyLibra® (norgestimate and ethinyl estradiol tablets, USP).
- Drugs.com: VyLibra Prices, Coupons, Copay Cards & Patient Assistance.
More… ↓